Comparative Pharmacology
Head-to-head clinical analysis: FLUDARA versus HALAVEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARA versus HALAVEN.
FLUDARA vs HALAVEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
None Documented
None Documented
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Clinical Note
moderateFludarabine + Digoxin
"Fludarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFludarabine + Digitoxin
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFludarabine + Deslanoside
"Fludarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFludarabine + Acetyldigitoxin
"Fludarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent